Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
Final survival analysis draws a blank, and Lantheus throws in the towel.
Conference activity picks up, with the big one – ASCO – at the end of the month.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Three off-the-shelf mRNA therapies join intismeran autogene.
Antibody-drug conjugates hitting this target abound.
